You searched for: aterotrombotičnih (Slovenska - Engelska)

preprečevanje aterotrombotičnih dogodko
prevention of atherothrombotic events

preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri atrijski fibrilaciji
prevention of atherothrombotic and thromboembolic events in atrial fibrillation

preprečevanje aterotrombotičnih dogodkov pri bolnikih po akutnem koronarnem sindromu
prevention of atherothrombotic events in patients after an acs

klopidogrel je indiciran pri odraslih za preprečevanje aterotrombotičnih dogodkov pri:
clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

zdravilo zontivity je indicirano za zmanjšanje aterotrombotičnih dogodkov pri odraslih bolnikih
zontivity is indicated for the reduction of atherothrombotic events in adult patients with

klopidogrel je indiciran pri odraslih za preprečevanje aterotrombotičnih dogodkov pri bolnikih z:
clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

zdravilo se je izkazalo za učinkovito pri zmanjševanju števila aterotrombotičnih dogodkov pri bolnikih, ki so doživeli srčni infarkt.
the medicine has been shown to be beneficial in reducing the number of atherothrombotic events in patients who had had a heart attack.

zato je treba uporabo zdravila possia pri bolnikih z večjim tveganjem krvavitev pretehtati v primerjavi s koristmi preprečevanja aterotrombotičnih dogodkov.
therefore, the use of possia in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events.

c: opazili občasno pri preprečevanju aterotrombotičnih dogodkov pri bolnikih po aks (po perkutanem koronarnem posegu)
c: observed as uncommon in prevention of atherothrombotic events in patients after an acs (following percutaneous coronary intervention)

skoraj vsi bolniki so obenem jemali tudi aspirin in/ali drugo zdravilo za preprečevanje aterotrombotičnih dogodkov ter so se zdravili vsaj eno leto.
nearly all patients also took aspirin and/or another medicine to prevent atherothrombotic events, and were treated for at least a year.

zdravilo brilique se uporablja tudi pri odraslih, ki so doživeli srčni infarkt pred enim letom ali več, in pri katerih obstaja veliko tveganje za nastanek aterotrombotičnih dogodkov.
brilique is also used in adults who had a heart attack a year or more ago and are at a high risk of an atherothrombotic event.

kadar se zdravilo xarelto uporablja za preprečevanje aterotrombotičnih dogodkov pri bolnikih, ki so imeli akutni koronarni sindrom, je priporočeni odmerek 2,5 mg dvakrat na dan.
when xarelto is used to prevent atherothrombotic events in patients who have had acute coronary syndrome, the recommended dose is 2.5 mg taken twice a day.

zdravilo clopidogrel acino pharma gmbh se uporablja pri odraslih za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost krvnih žil).
clopidogrel acino pharma gmbh is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).

uporabo ticagrelorja je treba pri bolnikih z večjim tveganjem krvavitev pretehtati v primerjavi s koristmi preprečevanja aterotrombotičnih dogodkov (glejte poglavji 4.8 in 5.1).
the use of ticagrelor in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events (see sections 4.8 and 5.1).

pri bolnikih s periferno arterijsko boleznijo so rezultati pokazali korist pri bolnikih, ki so jemali zdravilo zontivity, čeprav število aterotrombotičnih dogodkov, o katerih so poročali med glavno študijo, ni bilo zadostno za dokončen rezultat.
in patients with peripheral arterial disease, the data showed a benefit for patients taking zontivity, although the number of atherothrombotic events reported during the main study was not large enough to enable conclusive results.

pri bolnikih, zdravljenih za preprečevanje aterotrombotičnih dogodkov po akutnem koronarnem sindromu (aks), so poročali o krvavitvah vseh vrst in resnosti s pogostnostjo 22 na 100 bolnikov-let.
in patients treated for prevention of atherothrombotic events after an acute coronary syndrome (acs), bleeding of any type or severity was reported with an event rate of 22 per 100 patient years.

odbor za zdravila za uporabo v humani medicini (chmp) je zaključil, da so koristi zdravila clopidogrel bms za bolnike, pri katerih obstaja nevarnost aterotrombotičnih dogodkov, večje od z njim povezanih tveganj.
the committee for medicinal products for human use (chmp) decided that clopidogrel bms’s benefits are greater than its risks in adults for the prevention of atherothrombotic events.